This work is licensed under the Creative Commons Attribution 4.0 International License.
[Internet]. . Who.int. 2020 [cited 2020 Jun 25]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200608-covid-19-sitrep-140.pdf?sfvrsn=2f310900_2[Internet]. Who.int. 2020 [cited 2020 Jun 25]Available fromhttps://www.who.int/docs/default-source/coronaviruse/situation-reports/20200608-covid-19-sitrep-140.pdf?sfvrsn=2f310900_2Search in Google Scholar
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.YangXYuYXuJet alClinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir Med20208547548110.1016/S2213-2600(20)30079-5Search in Google Scholar
Cummings M, Baldwin M, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763-1770.CummingsMBaldwinMAbramsDet alEpidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort studyLancet2020395102391763177010.1016/S0140-6736(20)31189-2Search in Google Scholar
Bhatraju P, Ghassemieh B, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seatle Region — Case Series. N Engl J Med. 2020;382(21):2012-2022.BhatrajuPGhassemiehBNicholsMet alCovid-19 in Critically Ill Patients in the Seatle Region — Case SeriesN Engl J Med2020382212012202210.1056/NEJMoa2004500714316432227758Search in Google Scholar
Berlin DA, Gulick RM, Martinez FJ Severe Covid-19. Published online May 15th, 2020 DOI: https://doi.org/10.1056/NEJMcp2009575BerlinDAGulickRMMartinez FJ Severe Covid-19Published online May 15th2020https://doi.org/10.1056/NEJMcp200957510.1056/NEJMcp200957532412710Search in Google Scholar
Tabrizi M, Schinco M, Tepas J, et al. Inhaled epoprostenol improves oxygenation in severe hypoxemia. J Trauma Acute Care Surg. 2012;73(2):503-506.TabriziMSchincoMTepasJet alInhaled epoprostenol improves oxygenation in severe hypoxemiaJ Trauma Acute Care Surg201273250350610.1097/TA.0b013e318258431e23019678Search in Google Scholar
Alessandri F, Pugliese F, Ranieri V. The Role of Rescue Therapies in the Treatment of Severe ARDS. Respir Care. 2017;63(1):92101.AlessandriFPuglieseFRanieriVThe Role of Rescue Therapies in the Treatment of Severe ARDSRespir Care20176319210110.4187/respcare.0575229066591Search in Google Scholar
Duan E, Adhikari N, D’Aragon F, et al. Management of Acute Respiratory Distress Syndrome and Refractory Hypoxemia. A Multicenter Observational Study. Ann Am Thorac Soc. 2017;14(12):1818-1826.DuanEAdhikariND’AragonFet alManagement of Acute Respiratory Distress Syndrome and Refractory HypoxemiaA Multicenter Observational Study. Ann Am Thorac Soc201714121818182610.1513/AnnalsATS.201612-1042OC28910146Search in Google Scholar
Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. N Engl J Med. 2000;342(18):1301-1308.Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeN Engl J Med2000342181301130810.1056/NEJM20000504342180110793162Search in Google Scholar
Wiedemann H, Wheeler A, Bernard G. Comparison of two fluid-management strategies in acute lung injury. J Vasc Surg. 2006;44(4):909.WiedemannHWheelerABernardGComparison of two fluid-management strategies in acute lung injuryJ Vasc Surg200644490910.1016/j.jvs.2006.08.053Search in Google Scholar
Briel M, Meade M, Mercat A, et al. Higher versus lower positive end-expiratory pressure in acute lung injury and acute respiratory distress syndrome: systematic review and individual patient data meta-analysis. Crit Care. 2010;14(Suppl 1): P182.BrielMMeadeMMercatAet alHigher versus lower positive end-expiratory pressure in acute lung injury and acute respiratory distress syndrome: systematic review and individual patient data meta-analysisCrit Care201014Suppl 1P18210.1186/cc8414Search in Google Scholar
Alhazzani W, Møller M, Arabi Y, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020;48(6):e440-e469.AlhazzaniWMøllerMArabiYet alSurviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)Crit Care Med2020486e440e46910.1097/CCM.0000000000004363717626432224769Search in Google Scholar
Fuller B, Mohr N, Skrupky L, Fowler S, Kollef M, Carpenter C. The Use of Inhaled Prostaglandins in Patients With ARDS. Chest. 2015;147(6):1510-1522.FullerBMohrNSkrupkyLFowlerSKollefMCarpenterCThe Use of Inhaled Prostaglandins in Patients With ARDSChest201514761510152210.1378/chest.14-3161445170725742022Search in Google Scholar
Dzierba A, Abel E, Buckley M, Lat I. A Review of Inhaled Nitric Oxide and Aerosolized Epoprostenol in Acute Lung Injury or Acute Respiratory Distress Syndrome. Pharmacotherapy. 2013;34(3):279-290.DzierbaAAbelEBuckleyMLatIA Review of Inhaled Nitric Oxide and Aerosolized Epoprostenol in Acute Lung Injury or Acute Respiratory Distress SyndromePharmacotherapy201334327929010.1002/phar.136524734313Search in Google Scholar
Torbic H, Szumita P, Anger K, et al. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. J Crit Care. 2013;28(5):844-848.TorbicHSzumitaPAngerKet alInhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patientsJ Crit Care201328584484810.1016/j.jcrc.2013.03.00623683572Search in Google Scholar
Searcy R, Morales J, Ferreira J, Johnson D. The role of inhaled prostacyclin in treating acute respiratory distress syndrome. Ther Adv in Respir Dis. 2015;9(6):302-312.SearcyRMoralesJFerreiraJJohnsonDThe role of inhaled prostacyclin in treating acute respiratory distress syndromeTher Adv in Respir Dis20159630231210.1177/175346581559934526294418Search in Google Scholar
Dellinger R, Zimmerman J, Taylor R, et al. Efects of inhaled nitric oxide in patients with acute respiratory distress syndrome. Crit Care Med. 1998;26(1):15-23.DellingerRZimmermanJTaylorRet alEfects of inhaled nitric oxide in patients with acute respiratory distress syndromeCrit Care Med1998261152310.1097/00003246-199801000-000119428538Search in Google Scholar
Fallah F. Recent Strategies in Treatment of Pulmonary Arterial Hypertension, A Review. Glob J of Health Sci. 2015Jan25;7(4).FallahFRecent Strategies in Treatment of Pulmonary Arterial Hypertension, A ReviewGlob J of Health Sci2015Jan257410.5539/gjhs.v7n4p307480218325946920Search in Google Scholar
De Wet CJ, Afleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, efective, and afordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004;127(4):1058–67.De WetCJAfleckDGJacobsohnEet alInhaled prostacyclin is safe, efective, and afordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgeryJ Thorac Cardiovasc Surg2004127410586710.1016/j.jtcvs.2003.11.03515052203Search in Google Scholar
Epoprostenol [package insert]. . Federal Drug Administration: GlaxoSmithKline; 1995.Epoprostenol [package insert]Federal Drug Administration: GlaxoSmithKline;1995Search in Google Scholar
Liu X, Wang X-J. Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics. 2020:20;47(2):119-121.LiuXWangX-JPotential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicinesJ Genet Genomics20202047211912110.1101/2020.01.29.924100Search in Google Scholar
Rismanbaf A. Potential Treatments for COVID-19; a Narrative Literature Review. Arch Acad Emerg Med. 2020;8(1).RismanbafAPotential Treatments for COVID-19; a Narrative Literature ReviewArch Acad Emerg Med202081Search in Google Scholar
Farag A, Wang P, Ahmed M, Sadek H. Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning (Version 2). ChemRxiv. Published online 2020; DOI: doi.org/10.26434/chemrxiv.12003930.v2FaragAWangPAhmedMSadekHIdentification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning (Version 2). ChemRxivPublished online2020doi.org/10.26434/chemrxiv.12003930.v2Open DOISearch in Google Scholar
COVID View, Key Updates for Week 22 [Internet]. Centers for Disease Control and Prevention. 2020 [accessed 2020 June 7th]. Available from: https://www.cdc.gov/coronavirus/2019ncov/covid-data/covidview/index.htmlCOVID ViewKey Updates for Week 22 [Internet]Centers for Disease Control and Prevention2020[accessed 2020 June 7th]. Available fromhttps://www.cdc.gov/coronavirus/2019ncov/covid-data/covidview/index.htmlSearch in Google Scholar
Feng Y, Amoateng-Adjepong Y, Kaufman D, Gheorghe C, Manthous C. Age, Duration of Mechanical Ventilation, and Outcomes of Patients Who Are Critically Ill. Chest. 2009;136(3):759-764.FengYAmoateng-AdjepongYKaufmanDGheorgheCManthousCAge, Duration of Mechanical Ventilation, and Outcomes of Patients Who Are Critically IllChest2009136375976410.1378/chest.09-051519736189Search in Google Scholar
Ware L, Mathay M. The Acute Respiratory Distress Syndrome. N Engl J Med. 2000;342(18):1334-1349.WareLMathayMThe Acute Respiratory Distress SyndromeN Engl J Med2000342181334134910.1056/NEJM20000504342180610793167Search in Google Scholar
Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admited to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574.GrasselliGZangrilloAZanellaAet alBaseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admited to ICUs of the Lombardy Region, ItalyJAMA202032316157410.1001/jama.2020.5394713685532250385Search in Google Scholar
Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(6):16711677.ZwisslerBKemmingGHablerOet alInhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndromeAm J Respir Crit Care Med199615461671167710.1164/ajrccm.154.6.89703538970353Search in Google Scholar
Bernard G, Artigas A, Brigham K, et al. Report of the American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination. Intensive Care Med. 1994;20(3):225-232.BernardGArtigasABrighamKet alReport of the American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordinationIntensive Care Med199420322523210.1007/BF017047078014293Search in Google Scholar
DeGrado J, Szumita PM, Schuler BR, et al. Evaluation of the Eficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients with Coronavirus Disease 2019. Crit Care Explore. 2020;2(10):e0259DeGradoJSzumitaPMSchulerBRet alEvaluation of the Eficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients with Coronavirus Disease 2019Crit Care Explore2020210e025910.1097/CCE.0000000000000259758106633134949Search in Google Scholar
Sonti R, Pike CW, Cobb N. Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19. J Intensive Care Med. 2021;36(3):327-333.SontiRPikeCWCobbNResponsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19J Intensive Care Med202136332733310.1177/0885066620976525772425333234007Search in Google Scholar